title: Eosinophilic fasciitis in children frequently progresses to scleroderma-like cutaneous fibrosis.
abstract: We evaluated longterm outcome in 21 pediatric patients with biopsy proven eosinophilic fasciitis (EF), 4 followed in our rheumatology clinic and 17 reported in the literature. Two-thirds of these patients developed residual cutaneous fibrosis, while one-third enjoyed complete resolution of disease. Children under age 7 years were twice as likely as those over age 7 years to experience disease progression to cutaneous fibrosis [relative risk = 2.0 (95% confidence intervals 1.2, 3.4)]. Fourteen of 17 patients with extensive disease at diagnosis (involvement of 3-4 extremities +/- trunk) progressed to cutaneous fibrosis whereas all 4 patients with minimal disease (involvement of 1-2 extremities) at onset resolved completely. We detected no association between progression to cutaneous fibrosis and sex of patient, duration of symptoms prior to therapy, type of therapy, history of prior physical stress, or laboratory variables at diagnosis.
authors.affiliation: Department of Pediatrics, University of Washington, Seattle 98195.
authors.forename: M L
authors.initials: ML
authors.lastname: Farrington
authors.forename: J E
authors.initials: JE
authors.lastname: Haas
authors.forename: V
authors.initials: V
authors.lastname: Nazar-Stewart
authors.forename: E D
authors.initials: ED
authors.lastname: Mellins
mesh_terms: D000293:Adolescent; D001706:Biopsy; D002648:Child; D002675:Child, Preschool; D004802:Eosinophilia / Q000188:drug therapy / Q000473:pathology*; D005208:Fasciitis / Q000188:drug therapy / Q000473:pathology*; D005260:Female; D005355:Fibrosis; D006801:Humans; D008297:Male; D010396:Penicillamine / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D012594:Scleroderma, Localized / Q000473:pathology*; D012867:Skin / Q000473:pathology*; D016896:Treatment Outcome
chemical_list: D010396:Penicillamine; D011241:Prednisone